472 abstracts found.



Results filter

Targeting FOXM1 as a therapeutic strategy in cancer

Year:

Session type:

Theme:

Rebecca Downing1,Marta O. Freitas1,Wai Yiu Tse1,Sarah A. Martin1
1Barts Cancer Institute

The role of Senataxin in radiobiological hypoxia

Year:

Session type:

Theme:

Shaliny Ramachandran1,Pedro Victori1,Iosifina Foskolou1,Katarzyna Leszczynska1,Kienan Savage2,Ester Hammond1
1University of Oxford,2Queen’s University Belfast

Overcoming resistance to arginine deprivation therapy in Malignant Pleural Mesothelioma

Year:

Session type:

Theme:

Marta Freitas1,Peter Szlosarek1,Sarah A. Martin1
1Barts Cancer Institute

Non-Random Mis-Segregation of Human Chromosomes.

Year:

Session type:

Theme:

Sarah McClelland1,Joseph Worrall2,Naoka Tamura1,Alice Mazzagatti1,Nadeem Shaikh1,Tineke van Lingen1,Bjorn Bakker3,Elina Vladimirou4,Floris Foijer3
1Barts Cancer Institute,2Barts Cancer Institute, Queen Mary University of London,3ERIBA,4UCL Cancer Institute

Can CRISPR/Cas9 screens find new synthetic lethal targets for cancer ?

Year:

Session type:

Theme:

Jon Moore1
1Horizon Discovery

[10]-gingerol increases doxorubicin antitumoural and antimetastatic activity while decreases its undesired side effects in a triple negative breast cancer mouse model

Year:

Session type:

Theme:

Ana Carolina Martin1,Rebeka Tomasin1,Marina Naves1,Angelica Graminha1,Liany Luna-Dulcey1,Ramon Teles1,Marcia Cominetti1
1Federal University of São Carlos

Validation of putative metastasis suppressor genes identified by an in vivo functional shRNA screen in a triple-negative breast cancer model

Year:

Session type:

Theme:

Rebeka Tomasin1,Richard Redvers2,Marcia Cominetti1,Kaylene Simpson3,Robin Anderson2
1Federal University of São Carlos,2Olivia Newton John Cancer Research Institute,3Peter MacCallum Cancer Centre - Victorian Comprehensive Cancer Research Institute

A Predictive model of ‘on target’ drug resistance

Year:

Session type:

Theme:

Daniel O'Neill1,Mike Firth1,Maryam Clausen1,Jonathan Wrigley1,Emanuela Cuomo1
1AstraZeneca

Development of first-in-class USP7 inhibitors using structure-based design

Year:

Session type:

Theme:

Andrew Turnbull1,Stephanos Ioannidis2,Wojciech Krajewski3,Adan Pinto-Fernandez4,Claire Heride5,Agnes Martin3,Louise Tonkin3,Elizabeth Townsend2,Shane Buker2,David Lancia Jr.2,Christopher Dinsmore2,Tim Hammonds3,Sunkyu Kim2,Sylvie Urbe5,Michael Clague5,Benedikt Kessler4,David Komander6
1cancer research technology ltd,2FORMA Therapeutics,3CRUK Therapeutic Discovery Laboratories,4Oxford University,5Liverpool University,6Medical Research Council Laboratory of Molecular Biology

The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer

Year:

Session type:

Theme:

Sandra Van Schaeybroeck1,Nicholas Forsythe1,Alaa Refaat1,Arman Javadi1,Hajrah Khawaja1,Jessica-Ann Weir1,Heba Emam1,Wendy Allen1,Frank Burkamp2,Vlad Popovici3,Puthen Jithesh4,Claudio Isella5,Melissa Labonte1,Ian Mills1,Patrick Johnston1
1Queen's University Belfast,2Almac Discovery Laboratories,3Masarykova Univerzita,4Sidra Medical and Research Centre,5University of Torino School of Medicine